Literature DB >> 7571011

Alternatively spliced isoforms of the NMDARI receptor subunit.

R S Zukin1, M V Bennett.   

Abstract

Molecularly diverse forms of the NMDA-receptor subunit NRI are formed by alternative RNA splicing. Differential splicing of three exons generates as many as eight NRI splice variants, seven of which have been identified in cDNA libraries. The alternatively spliced exons encode a 21 amino acid sequence in the N-terminus domain (termed NI), and adjacent sequences of 37 and 38 amino acids in the C-terminus domain (termed C1 and C2, respectively). Splicing out the exon segment that encodes the C2 cassette removes the first stop codon, resulting in a new open reading frame that encodes an unrelated sequence of 22 amino acids (C2') before a second stop codon is reached. Differential RNA splicing alters the structural, physiological and pharmacological properties of receptors that comprise NRI subunits. Diversity of NMDA receptors is also caused by differential association with members of the NR2 gene family. The finding of cell-specific expression and developmental regulation of NRI splice variants, and of the NR2 subunits, provides an explanation for the diversity of properties of NMDA receptors in different neuronal populations.

Mesh:

Substances:

Year:  1995        PMID: 7571011     DOI: 10.1016/0166-2236(95)93920-s

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  108 in total

1.  Effect of enriched environment rearing on impairments in cortical excitability and plasticity after prenatal alcohol exposure.

Authors:  V Rema; F F Ebner
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  A biophysical model of bidirectional synaptic plasticity: dependence on AMPA and NMDA receptors.

Authors:  G C Castellani; E M Quinlan; L N Cooper; H Z Shouval
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

3.  Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing.

Authors:  M Brudno; M S Gelfand; S Spengler; M Zorn; I Dubchak; J G Conboy
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

4.  GluN1 splice variant control of GluN1/GluN2D NMDA receptors.

Authors:  Katie M Vance; Kasper B Hansen; Stephen F Traynelis
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

5.  Glutamate receptor subunit expression in the rhesus macaque locus coeruleus.

Authors:  Nigel C Noriega; Vasilios T Garyfallou; Steven G Kohama; Henryk F Urbanski
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

6.  Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure.

Authors:  B Lewis; K A Wellmann; S Barron
Journal:  Pharmacol Biochem Behav       Date:  2007-07-25       Impact factor: 3.533

7.  A peripheral neuroimmune link: glutamate agonists upregulate NMDA NR1 receptor mRNA and protein, vimentin, TNF-alpha, and RANTES in cultured human synoviocytes.

Authors:  Terry A McNearney; Yinghong Ma; Yueping Chen; Giulio Taglialatela; Huaizhi Yin; Wen-Ru Zhang; Karin N Westlund
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-09       Impact factor: 3.619

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

9.  Activity-dependent anchoring of importin alpha at the synapse involves regulated binding to the cytoplasmic tail of the NR1-1a subunit of the NMDA receptor.

Authors:  Rachel A Jeffrey; Toh Hean Ch'ng; Thomas J O'Dell; Kelsey C Martin
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

10.  Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity.

Authors:  C Geoffrey Lau; Koichi Takeuchi; Alma Rodenas-Ruano; Yukihiro Takayasu; Jessica Murphy; Michael V L Bennett; R Suzanne Zukin
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.